For startups

Biotica Bio helps founders and R&D teams move faster with evidence, not guesswork.

What we offer

• Investor narratives — Target validation and indication rationale grounded in Open Targets data, so your story is credible and reproducible.
• Partner and BD discussions — Clear biology, disease association, and druggability summaries for out-licensing or collaboration talks.
• Pipeline prioritisation and benchmarking — Compare and benchmark drug, target, and indication potential on the same Open Targets evidence base so you can focus on the best opportunities.
• Competitive context — See how your targets sit in the landscape and where differentiation (combination, biomarker, formulation) matters most.
• Updates as data changes — Re-run the same assessment when Open Targets or other evidence updates; we can support ongoing monitoring.

The Open Targets Platform is the same evidence base that big pharma and academia use: integrated targets, diseases, drugs, and scored associations. We turn it into formats that work at your pace—credible, reproducible, and updatable.